期刊文献+

阿达木单抗治疗重度银屑病的疗效观察 被引量:4

Analysis of the efficacy of adalimumab in the treatment of severe psoriasis
下载PDF
导出
摘要 目的观察阿达木单抗治疗重度银屑病的效果。方法在我院皮肤科2016年9月~2018年10月收治的重度银屑病患者中选出135例为对象,随机将患者分为对照组和观察组,对照组患者给予常规西医治疗(阿维A、雷公藤多苷片和卡西醇软膏),观察组患者在对照组基础上应用阿达木单抗治疗,对比两组的治疗总有效率等。结果观察组治疗总有效率为95.52%,高于对照组治疗总有效率(82.35%),P<0.05;不良反应发生率对比,观察组13.43%,与对照组17.65%差异不明显,P>0.05。结论阿达木单抗在重度银屑病患者治疗中的应用效果确切,且用药安全性高。 Objective To investigate the effect of adalimumab in the treatment of severe psoriasis.Methods 135 patients with severe psoriasis were selected from the Dermatology Department of our hospital from September 2016 to October 2018.The patients were randomly divided into two groups.The patients in the control group were treated with conventional western medicine(Avera,Tripterygium wilfordii polyglycoside tablets and Cassitol ointment).The patients in the observation group were treated with adamumab on the basis of the control group,and the total effective rate of the two groups was compared.Results The total effective rate of the observation group was 95.52%,which was higher than the total effective rate of the control group of 82.35%,P<0.05.Comparison of adverse reaction incidence:there was no significant difference between the observation group(13.43%)and the control group(17.65%,P>0.05).Conclusion The application of adalimumab in the treatment of patients with severe psoriasis is accurate and the drug safety is high.
作者 易多奇 胡晓舒 毛振坤 YI Duo-qi;HU Xiao-shu;MAO Zhen-kun(Department of Skin and Beauty,Sanhe Hospital,Huiyang,Guangdong 516000)
出处 《皮肤病与性病》 2020年第1期3-4,共2页 Dermatology and Venereology
关键词 阿达木单抗 重度银屑病 生物制剂 不良反应 Adalimumab Severe psoriasis Biological agents Adverse reactions
  • 相关文献

参考文献5

二级参考文献62

  • 1马道铭.维生素D_3和银屑病[J].国外医学(皮肤性病学分册),1996,22(1):1-4. 被引量:4
  • 2Griffiths CE.The immunological basis of psoriasis[J].J Eur AcadDermatol Venereol,2003,17(2):1-5.
  • 3Arican O,Aral M,Sasmaz S,et al.Serum levels of TNF-alpha,IFN-gamma,IL-6,IL-8,IL-12,IL-17,and IL-18 in patients with activepsoriasis and correlation with disease severity[J].Mediators In-flamm,2005(5):273.
  • 4Oppenheim J,Feldmann M.Cytokine reference[M].San Diego:Aca-demic Press,2000:125.
  • 5Ouyang W,Kolls JK,Zheng Y.The biological functions of T helper17 cell effector cytokines in inflammation[J].Immunity,2008,28(4):454-4.67.
  • 6Wittmann DH,Schein M,Condon R.Management'of secondary peri-tioitis[J].Ann Surg,1996,244(1):10-18.
  • 7Rampart M,Fiers W,De smet W,et al.Different pro-inflammatoryprofiles of interleukin-1 and tumor necrosis factor in an in vivo modelof inflammation[J].Agents Aetions,1989 ’26(1-2):186-188.
  • 8Pohlman TH,Stanness KA,Beatty PG,et al.An endothelial cell sur-face factor(s)induced in vitro by Iipopolysaccharide,interleukin-1,and tumor necrosis factor-alpha increases neutrophil adherence by aCDW 18-dependent mechanism[J].J Immunol,1986,136(12):4548 4553.
  • 9Yao Z,Li P,Zhang Q,et al.Tumor necrosis factor-alpha increasescirculating osteoclast precursor numbers by promoting their prolifera-tion and differentiation in the bone marrow through up-regulation ofc-Fms expression[J].J Bio Chem,2006,281(17):11846-.11855.
  • 10Zaba LC,Cardinale I,Gilleaudeau P,et al.Amelioration of epider-mal hyperplasia by TNF inhibition is associated with reduced Thl 7responses[J].J Exp Med,2007,204(13):3183-3194.

共引文献30

同被引文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部